MCID: PNC006
MIFTS: 38

Pancreatic Somatostatinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Somatostatinoma

MalaCards integrated aliases for Pancreatic Somatostatinoma:

Name: Pancreatic Somatostatinoma 38 12 15 73
Pancreatic Delta Cell Somatostatin Producing Neoplasm 12
Pancreatic Somatostatin Cell Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4432
NCIt 50 C8006 C95595
UMLS 73 C1368041

Summaries for Pancreatic Somatostatinoma

MalaCards based summary : Pancreatic Somatostatinoma, also known as pancreatic delta cell somatostatin producing neoplasm, is related to somatostatinoma and intestinal pseudo-obstruction, and has symptoms including diarrhea An important gene associated with Pancreatic Somatostatinoma is SST (Somatostatin), and among its related pathways/superpathways is Neuroscience. The drugs Bevacizumab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, liver and pancreas.

Related Diseases for Pancreatic Somatostatinoma

Diseases related to Pancreatic Somatostatinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 somatostatinoma 31.7 CALCA ENO2 SST
2 intestinal pseudo-obstruction 29.9 SST SYP
3 duodenal somatostatinoma 28.2 CALCA ENO2 PPY SST
4 wdha syndrome 10.6 CALCA SST
5 prolactin producing pituitary tumor 10.5 CALCA SST
6 pancreatitis 10.5
7 pancreatic gastrinoma 10.5 MEN1 SST
8 hormone producing pituitary cancer 10.5 MEN1 SST
9 retinitis pigmentosa 40 10.4 PPY SST
10 functioning pituitary adenoma 10.4 MEN1 SST
11 zollinger-ellison syndrome 10.4 MEN1 SST
12 gastrinoma 10.4 MEN1 SST
13 multiple endocrine neoplasia, type iib 10.4 CALCA MEN1
14 malignant glandular tumor of peripheral nerve sheath 10.4 SST SYP
15 adenoma of the pancreas 10.4 SST SYP
16 gastrointestinal neuroendocrine tumor 10.4 SST SYP
17 fibrous dysplasia 10.3 CALCA SST
18 endocrine pancreas disease 10.3 PPY SST
19 pancreatoblastoma 10.3 SST SYP
20 endocrine organ benign neoplasm 10.3 MEN1 SST
21 ampulla of vater neoplasm 10.3 SST SYP
22 pituitary tumors 10.3 MEN1 SST
23 parathyroid gland disease 10.3 CALCA MEN1
24 serotonin syndrome 10.3 MEN1 SST
25 binswanger's disease 10.3 SST SYP
26 functional colonic disease 10.3 SST SYP
27 pancreas disease 10.3 PPY SST
28 multiple endocrine neoplasia, type iia 10.3 CALCA MEN1
29 pituitary gland disease 10.2 MEN1 SST
30 parathyroid carcinoma 10.2 CALCA MEN1
31 pancreatic cystadenocarcinoma 10.2 CALCA SYP
32 colonic pseudo-obstruction 10.2 SST SYP
33 multiple endocrine neoplasia 10.2 CALCA MEN1
34 tanycytic ependymoma 10.2 MEN1 SYP
35 non-functioning pancreatic endocrine tumor 10.2 PPY SYP
36 pituitary adenoma, prolactin-secreting 10.2 MEN1 SST
37 retroperitoneal neuroblastoma 10.1 ENO2 SST
38 constipation 10.1 CALCA SST
39 parathyroid adenoma 10.1 CALCA MEN1
40 acute thyroiditis 10.0 CALCA ENO2
41 small intestine cancer 10.0 ENO2 SST
42 diffuse pulmonary fibrosis 10.0 CALCA ENO2
43 acromegaly 10.0 MEN1 SST
44 islet cell tumor 10.0 CALCA MEN1 SST
45 cloacogenic carcinoma 10.0 CALCA ENO2
46 thyroid cancer, nonmedullary, 2 9.9 CALCA MEN1 SST
47 chondroid lipoma 9.9 ENO2 MEN1
48 hypoglycemia 9.9
49 insulinoma 9.9 MEN1 SST
50 ureter small cell carcinoma 9.9 ENO2 SYP

Graphical network of the top 20 diseases related to Pancreatic Somatostatinoma:



Diseases related to Pancreatic Somatostatinoma

Symptoms & Phenotypes for Pancreatic Somatostatinoma

UMLS symptoms related to Pancreatic Somatostatinoma:


diarrhea

Drugs & Therapeutics for Pancreatic Somatostatinoma

Drugs for Pancreatic Somatostatinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
4
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
8 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
9 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
10 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
11 Antimetabolites Phase 2, Phase 3,Phase 1
12 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
13 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
14 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
15 Adjuvants, Anesthesia Phase 3
16 Analgesics Phase 3
17 Analgesics, Opioid Phase 3
18 Anesthetics Phase 3
19 Anesthetics, General Phase 3
20 Anesthetics, Intravenous Phase 3
21 Central Nervous System Depressants Phase 3
22 Narcotics Phase 3
23 Peripheral Nervous System Agents Phase 3
24 Folate Nutraceutical Phase 2, Phase 3
25 Vitamin B9 Nutraceutical Phase 2, Phase 3
26 Cola Nutraceutical Phase 3,Phase 2,Phase 1
27
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
28
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
29
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
30
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
31
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
32
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
33
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
34
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
35
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
36
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
37
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
38
Octreotide Approved, Investigational Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
39
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
40
Pancrelipase Approved, Investigational Phase 2 53608-75-6
41
Melphalan Approved Phase 2 148-82-3 4053 460612
42
Somatostatin Approved, Investigational Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
43
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
44
Gemcitabine Approved Phase 2 95058-81-4 60750
45
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
46
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
47
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
49
Vatalanib Investigational Phase 2,Phase 1 212141-54-3 151194
50 Anti-Bacterial Agents Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
4 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
5 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
6 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
7 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
8 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
9 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
10 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
11 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
12 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
13 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
14 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
15 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
16 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
17 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
18 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
19 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
20 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Terminated NCT01056601 Phase 2 Bortezomib;Panobinostat
21 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
22 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
23 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
24 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
25 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
26 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
27 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
28 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
29 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
30 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
31 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
32 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
33 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376
34 Ga-DOTATOC Versus Octreoscan + CT Suspended NCT01869725 Not Applicable
35 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Terminated NCT00730483 Not Applicable PVA microporous hydrospheres/doxorubicin hydrochloride

Search NIH Clinical Center for Pancreatic Somatostatinoma

Genetic Tests for Pancreatic Somatostatinoma

Anatomical Context for Pancreatic Somatostatinoma

MalaCards organs/tissues related to Pancreatic Somatostatinoma:

41
Liver, Pancreas, Endothelial, Kidney, Bone, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Somatostatinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Delta Cells Affected by disease

Publications for Pancreatic Somatostatinoma

Articles related to Pancreatic Somatostatinoma:

(show all 31)
# Title Authors Year
1
Pancreatic somatostatinoma diagnosed preoperatively: report of a case. ( 24413789 )
2014
2
Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern. ( 20043348 )
2010
3
Cardiac metastasis from malignant pancreatic somatostatinoma. ( 19733881 )
2010
4
Pancreatic somatostatinoma with von Recklinghausen's disease. ( 18926936 )
2009
5
Pancreatic somatostatinoma characterized by extreme hypoglycemia. ( 19719976 )
2009
6
Pancreatic somatostatinoma manifested as severe hypoglycemia. ( 19565056 )
2009
7
Pancreatic somatostatinoma and tuberous sclerosis: case report of an exceedingly rare association. ( 18672238 )
2009
8
FNAC diagnosis of pancreatic somatostatinoma. ( 21938182 )
2009
9
Diagnosis and treatment of pancreatic somatostatinoma: a case report. ( 19080351 )
2008
10
Fine-needle aspiration cytology of pancreatic somatostatinoma: the importance of immunohistochemistry for the cytologic diagnosis of pancreatic endocrine neoplasms. ( 16007666 )
2005
11
A small, incidentally detected pancreatic somatostatinoma: report of a case. ( 12560911 )
2003
12
Periampullary pancreatic somatostatinoma. ( 12417508 )
2002
13
[Von Recklinghausen's disease associated with pancreatic somatostatinoma]. ( 11769067 )
2001
14
Reciprocal changes in progression of gastric mucosa-associated lymphoid tissue lymphoma and pancreatic somatostatinoma. ( 9870841 )
1998
15
Calcitonin-producing pancreatic somatostatinoma: report of a case. ( 9872549 )
1998
16
Brain metastasis from malignant pancreatic somatostatinoma. Case report. ( 8814175 )
1996
17
Pancreatic somatostatinoma presenting with chronic intestinal pseudo-obstruction syndrome. ( 17912215 )
1996
18
Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. ( 7745981 )
1995
19
Pancreatic somatostatinoma. ( 2077482 )
1990
20
Pancreatic somatostatinoma: a case report and review of the literature. ( 1969977 )
1990
21
Pancreatic somatostatinoma: presentation with recurrent episodes of severe hyperglycaemia and ketoacidosis. ( 2855274 )
1988
22
Malignant pancreatic somatostatinoma in a patient with dermatitis herpetiformis and coeliac disease. ( 2899527 )
1988
23
Pancreatic somatostatinoma. ( 6314830 )
1983
24
Pancreatic somatostatinoma: abundance of somatostatin-28(1-12)-like immunoreactivity in tumor and plasma. ( 6137494 )
1983
25
Pancreatic somatostatinoma. ( 6314831 )
1983
26
Pancreatic somatostatinoma presenting with hypoglycaemia. ( 6105026 )
1980
27
Calcitonin-producing pancreatic somatostatinoma. ( 6102950 )
1980
28
Molecular forms of somatostatin in normal subjects and in patients with pancreatic somatostatinoma. ( 6105027 )
1980
29
Pancreatic somatostatinoma: histologic, clinical, and angiographic features. ( 227259 )
1979
30
Calcitonin secretion by a pancreatic somatostatinoma. ( 714084 )
1978
31
Pancreatic somatostatinoma. Clinical features and physiological implications. ( 66472 )
1977

Variations for Pancreatic Somatostatinoma

Expression for Pancreatic Somatostatinoma

Search GEO for disease gene expression data for Pancreatic Somatostatinoma.

Pathways for Pancreatic Somatostatinoma

Pathways related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.33 CALCA ENO2 SYP

GO Terms for Pancreatic Somatostatinoma

Cellular components related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 terminal bouton GO:0043195 8.96 CALCA SYP
2 neuronal cell body GO:0043025 8.8 CALCA ENO2 SST

Biological processes related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.43 CALCA PPY SST
2 response to heat GO:0009408 9.16 CALCA SST
3 feeding behavior GO:0007631 8.96 CALCA PPY
4 cell-cell signaling GO:0007267 8.8 CALCA PPY SST

Molecular functions related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CALCA PPY SST

Sources for Pancreatic Somatostatinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....